Authoratory™
 
This website is accredited by Health On the Net Foundation. Click to verify.
ExcelCSVXML     print

1Anne-Marie Batt

 

Summary for 2003 [at-glance overview of Anne-Marie Batt work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author Anne-Marie Batt. According to available data, in 2003 Anne-Marie Batt published at least 1 articles. This work was completed in collaboration with several authors including Visvikis, Sophie and Siest, Gérard. There is no information about the funding or the grants awarded to support this work.

Analysis of the article abstracts and the titles suggests that Anne-Marie Batt professional interests are focused around "pharmacogenomics drugs affecting", "drugs affecting cardiovascular" and "affecting cardiovascular system". These might also be referred to as "cardiovascular drugs", "adverse effects" or "pharmacogenomics drugs". Statistical analysis shows that Anne-Marie Batt's writing is likely to contains terms "drugs", "cardiovascular", "metabolism", "variability", "drug" and "phase".

The majority of Anne-Marie Batt articles are affiliated with INSERM U 525, Centre du Médicament, Faculté de Pharmacie, Université Henri Poincaré Nancy I, Nancy, France. Luckily, one email address is on file.

Other [context-specific ads]

Alternative names (0) [other authors with names similar to Anne-Marie Batt]

  • none

Year 2003 Charts [Anne-Marie Batt frequent coauthors and the most common unique vocabulary terms for the selected year]

  • Anne-Marie Batt - Coauthors & Social Network in 2003Anne-Marie Batt - Unique Vocabulary, Keywords and Interests in 2003

Historical Performance Charts [graphical overview of Anne-Marie Batt publication and funding history for the range of years]

  • Anne-Marie Batt - Publications and Funding History in 2003

Emails (1) [email addresses extracted from Anne-Marie Batt affiliations]

hidden to prevent spam, click here to reveal

Anne-Marie Batt Coauthors (3) [all coauthors with the number of joint publications]

1

16Visvikis, Sophie

1

13Siest, Gérard

1

1Ferrari, Luc

 

Affiliations (1) [condensed summary of the Anne-Marie Batt affiliations, the leading number and the color conveys importance]

  • 1INSERM U 525, Centre du Médicament, Faculté de Pharmacie, Université Henri Poincaré Nancy I, Nancy, France.

Key Opinion Leader In [Anne-Marie Batt is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

  • no keywords assigned

Keywords (9) [keywords assigned to Anne-Marie Batt articles by PubMed, the leading number and the color conveys importance]

  • 1Humans | 1Pharmacogenetics | 1Cytochrome P-450 Enzyme System | 1Lipid Metabolism | 1Cardiovascular System | 1Cardiovascular Agents | 1Genotype | 1Polymorphism, Genetic | 1Mutation

Anne-Marie Batt Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Anne-Marie Batt might be a good expert witness on these terms]

  • 7drugs | 6cardiovascular | 3metabolism | 3variability | 3drug | 3phase | 2effects | 2pharmacogenomics | 2risk | 2transporters | 2affecting | 2response | 2among | 2system | 2adverse | 2proteins | 2enzymes | 2polymorphisms | 2human | 2targets | 1variation | 1impaired | 1approach | 1biochemical | 1identified | 1genetic | 1moved | 1best | 1genetics | 1emphasizing | 1cyp | 1variations
  • 3cardiovascular drugs | 2adverse effects | 2pharmacogenomics drugs | 2affecting cardiovascular | 2cardiovascular system | 2drugs affecting | 1p450 cyp | 1linked cardiovascular | 1possible consequences | 1targets proteins | 1variation receptors | 1pharmacogenomics | 1considered polymorphisms | 1risk | 1personalized genotype-dependent | 1system variability | 1efficacy adverse | 1phase enzymes | 1phase ii | 1partly genetics | 1various polymorphic | 1metabolism drugs | 1mainly indicated | 1drugs cyp3a4 | 1indicated best | 1best known | 1originates partly | 1drugs biotransformation | 1relevant metabolism | 1glutathion-s-transferase gsh-t | 1drug metabolism | 1including cytochromes
  • 2pharmacogenomics drugs affecting | 2drugs affecting cardiovascular | 2affecting cardiovascular system | 1moved approach personalized | 1cyp3a4 cyp2c9 cyp2c19 | 1system among relevant | 1risk concept emphasizing | 1human genome together | 1pharmacogenomics | 1angiotensin-converting enzyme beta-adrenergic | 1phase enzymes including | 1risk | 1cyp2c9 cyp2c19 cyp2d6 | 1system variability drug | 1must considered polymorphisms | 1revealed sources human | 1identified involved interindividual | 1family must considered | 1emphasizing impaired metabolism | 1targets proteins identified | 1transporters among pharmacological | 1various polymorphic phase | 1simultaneous progress knowledge | 1polymorphic phase enzymes | 1partly genetics possible | 1linked cardiovascular risk | 1source variability variability | 1cardiovascular drugs cyp3a4 | 1limited regard cardiovascular | 1pharmacological targets proteins | 1metabolized various polymorphic | 1interindividual variations response

Reader's Comments (0) [comments posted by readers of Anne-Marie Batt profile]

no comments yet

Funding (0) [selected NIH grants to Anne-Marie Batt and the award amounts for recent years]

  • award information is not available

Anne-Marie Batt Articles (1) [selected PubMed articles for the year 2003 with the links to a full text at PubMed]